NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.)’s NVC-422 Cleared by FDA for Human Clinical Trials in Ophthalmology

13 Jan 2009

·www.biospace.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX: NBY, ), announces the clearance of an Investigational New Drug application (IND) submitted by Alcon to the FDA to permit the clinical development of NovaBay’s NVC-422 for infections of the eye. The IND clearance has triggered the immediate payment of the first milestone of $1,000,000 from Alcon to NovaBay.

Organizations

NovaCal Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc.Luv N' Care Ltd.

Indications

Infectious Diseases

Targets

Drugs

Auriclosene

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.